MiRXES is a Singapore-headquartered biotechnology company whose mission is to improve and save lives through disease early detection tests. We are Asia-centered, starting with Southeast Asia, and have global ambitions. We have research, development, manufacturing, and clinical diagnostic operations in Singapore, USA, Japan, and China. We have sales and distribution networks worldwide. MiRXES flagship product is GASTROClear, the world’s first molecular blood test for early detection of gastric cancer, able to detect around 90% of patients with Stage I and II cancers.

MiRXES (觅瑞早筛)

MiRXES (觅瑞早筛)